Show Notes
Bell HW et al et al., Nature Communications - This study shows that CpG methylation at proximal HBG promoters causally enforces perinatal silencing and that targeted epigenome editing can reverse that silencing in cell models and primary erythroblasts. UHRF1 and the methyl-CpG reader MBD2 are key mediators of repression. Key terms: HBG, CpG methylation, UHRF1, MBD2, epigenome editing.
Study Highlights:
A CRISPR/Cas9 screen identified UHRF1 as a mediator of HBG repression; loss of UHRF1 causes global CpG demethylation and HBG activation. Targeted dCas9–TET1 (TETv4) demethylation of the HBG proximal promoters activates HBG in HUDEP2 cells and primary CD34+ erythroblasts, while targeted dCas9–DNMT3A–DNMT3L re-methylation restores repression. Mutation of the MBD2 methyl-CpG binding domain (Y178F) impairs methyl-CpG binding and derepresses HBG, supporting a model in which promoter CpG methylation recruits MBD2-NuRD to silence HBG.
Conclusion:
Localized CpG methylation at HBG proximal promoters is sufficient to silence the genes; targeted promoter demethylation reactivates HBG and offers a potential, more specific epigenomic strategy to induce therapeutic fetal hemoglobin for β-hemoglobinopathies.
Music:
Enjoy the music based on this article at the end of the episode.
Article title:
Removal of promoter CpG methylation by epigenome editing reverses HBG silencing
First author:
Bell HW et al
Journal:
Nature Communications
DOI:
10.1038/s41467-025-62177-z
Reference:
Bell HW et al., Removal of promoter CpG methylation by epigenome editing reverses HBG silencing. Nature Communications (2025). DOI: 10.1038/s41467-025-62177-z
License:
This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/
Support:
Base by Base – Stripe donations: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00
Official website https://basebybase.com
On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics.
Episode link: https://basebybase.com/episodes/removal-promoter-cpg-methylation-hbg
QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-08-16.
QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music
- transcript coverage: Audited the transcript’s coverage of promoter CpG methylation as a causal silencer of HBG, the role of UHRF1, targeted epigenome editing (TETv4 and D3AL), the MBD2-NuRD mechanism (including MBD2 Y178F), and validation in HUDEP2 and CD34+ erythroblasts, plus implications for HbF therapy.
- transcript topics: Promoter CpG methylation silences HBG; UHRF1 as maintenance methylation factor in HbF repression; Epigenome editing with TETv4 to demethylate HBG promoters; Durability of HBG activation in HUDEP2 cells; D3AL remethylation reverses activation; MBD2-NuRD complex and MBD2 Y178F mutation
QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 6
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0
Metadata Audited:
- article_doi
- article_title
- article_journal
- license
Factual Items Audited:
- UHRF1 maintains CpG methylation to repress HBG; disruption leads to demethylation and HBG activation
- Local promoter demethylation via targeted epigenome editing (TETv4) activates HBG in HUDEP2 and primary CD34+ erythroblasts, with robust expression (up to ~86% HbF/HBG)
- Remethylation of HBG promoters by D3AL reverses activation, reducing HBG expression (to ~23%)
- Activation requires demethylation across multiple CpG sites upstream of the TSS, not a single CpG
- MBD2 Y178F mutation impairs methyl-CpG binding and derepresses HBG, illustrating MBD2-NuRD’s key role
- MBD2-NuRD recruitment is linked to HBG silencing; BCL11A occupancy can persist even after demethylation
QC result: Pass.
